Mark Gompels

North Bristol NHS Trust — United Kingdom

Medicine · Health Sciences

41h-index8.1kcitations179works11.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV/AIDS Research and Interventions(53), HIV/AIDS drug development and treatment(45), HIV Research and Treatment(43), Coagulation, Bradykinin, Polyphosphates, and Angioedema(28), HIV-related health complications and treatments(27)

Publications158 total

Chronic norovirus infection in immunodeficiency: A UK national case series
The Journal of Allergy and Clinical Immunology In Practice·2025· 1 cited
Long-Term Prophylactic Treatment with Oral Deucrictibant Improves Health-Related Quality of Life of Patients with Hereditary Angioedema: CHAPTER-1 Open-Label Extension Study
Journal of Allergy and Clinical Immunology·2025
Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study
Journal of Allergy and Clinical Immunology·2025
A patient with CVID-enteropathy successfully treated with ustekinumab
Immunologic Research·2024· 3 cited
Is Proton Therapy for Synchronous Bilateral Breast Cancer a Medical Necessity?
International Journal of Radiation Oncology*Biology*Physics·2024Open Access
Investigating pulmonary and non-infectious complications in common variable immunodeficiency disorders: a UK national multi-centre study
Frontiers in Immunology·2024· 8 citedOpen Access
805 Topical thyroid hormones promote hair follicle and epithelial hair follicle stem cell growth in intact human scalp skin ex vivo
Journal of Investigative Dermatology·2024Open Access
Efficacy and Safety of Donidalorsen for Hereditary Angioedema
New England Journal of Medicine·2024· 49 citedOpen Access
Definition, acronyms, nomenclature, and classification of angioedema (DANCE): AAAAI, ACAAI, ACARE, and APAAACI DANCE consensus
Journal of Allergy and Clinical Immunology·2024· 82 citedOpen Access
A Core Outcome Set for Efficacy of Acute Treatment of Hereditary Angioedema
The Journal of Allergy and Clinical Immunology In Practice·2024· 5 citedOpen Access
Prophylaxis in hereditary angioedema: a United Kingdom Delphi consensus
Clinical & Experimental Immunology·2024· 3 citedOpen Access
Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT)
EClinicalMedicine·2024· 3 citedOpen Access
Efficacy And Safety Of Bradykinin B2 Receptor Antagonism With Oral Deucrictibant In Prophylaxis Of Hereditary Angioedema Attacks: Results Of CHAPTER-1 Phase 2 Trial
Journal of Allergy and Clinical Immunology·2024· 7 citedOpen Access
Peripheral Neuropathy in Virologically Suppressed People Living with HIV: Evidence from the PIVOT Trial
Viruses·2023· 5 citedOpen Access
Rate of response to initial antiretroviral therapy according to level of pre‐existing HIV‐1 drug resistance detected by next‐generation sequencing in the strategic timing of antiretroviral treatment (START) study
HIV Medicine·2023· 5 citedOpen Access
The incidence of physician‐diagnosed food allergy declines with age: A specialist UK centre experience
Clinical & Experimental Allergy·2023
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir
Journal of Antimicrobial Chemotherapy·2023· 2 citedOpen Access
Hepmarc: A 96 week randomised controlled feasibility trial of add-on maraviroc in people with HIV and non-alcoholic fatty liver disease
PLoS ONE·2023· 8 citedOpen Access
Chronic or recurrent Campylobacter enteritis in primary immunodeficiency: A UK national case-series and review of the literature
The Journal of Allergy and Clinical Immunology In Practice·2023· 5 citedOpen Access
Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 Trial
Clinical Infectious Diseases·2023· 18 citedOpen Access
page 1 of 8Next →

Frequent Co-authors

Clifford Leen(19), Margaret Johnson(16), Caroline Sabin(14), Richard Gilson(13), Chloe Orkin(12), Jane Anderson(12), Andrew Phillips(10), John Walsh(10), Martin Fisher(10), Hilary Longhurst(10), Teresa Hill(9), Mark Nelson(9), David Dunn(9), Brian Gazzard(9), Adrian Palfreeman(8), Jonathan Ainsworth(8), Henriette Farkas(7), Achim Schwenk(7), Sarah Johnston(6), R J Lock(6)